BRIEF-Beam Therapeutics Says All 7 Patients Treated With Beam-101 Achieved Durable Increases In Fetal Hemoglobin, Reductions In Sickle Hemoglobin

Reuters12-08

Dec 7 (Reuters) - Beam Therapeutics Inc :

* BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING

* BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

* BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489221773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-08 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489221773","market":"us","top_or_hot":-1,"title":"BRIEF-Beam Therapeutics Says All 7 Patients Treated With Beam-101 Achieved Durable Increases In Fetal Hemoglobin, Reductions In Sickle Hemoglobin","media":"Reuters","content":"<html><body><p>Dec 7 (Reuters) - Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING</p><p>   * BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION</p><p>   * BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN</p><p> Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Beam Therapeutics Says All 7 Patients Treated With Beam-101 Achieved Durable Increases In Fetal Hemoglobin, Reductions In Sickle Hemoglobin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Beam Therapeutics Says All 7 Patients Treated With Beam-101 Achieved Durable Increases In Fetal Hemoglobin, Reductions In Sickle Hemoglobin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-08 00:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dec 7 (Reuters) - Beam Therapeutics Inc   :   * BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING   * BEAM THERAPEUTICS...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BEAM","symbol_name":"Beam Therapeutics, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2489221773","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489221773","pubTimestamp":1733589003,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 7  - Beam Therapeutics Inc   :   * BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING   * BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION   * BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BEAM":"Beam Therapeutics, Inc.","BK4535":"淡马锡持仓","LENZ":"Therapeutics","BK4505":"高瓴资本持仓","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股"},"translate_title":"BRIEF-Beam Therapeutics表示，所有7名接受Beam-101治疗的患者均实现了胎儿血红蛋白的持久增加和镰状血红蛋白的减少","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"BEAM":0.9},"content_text":"Dec 7 (Reuters) - Beam Therapeutics Inc   :   * BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING   * BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION   * BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489221773"}